Related references
Note: Only part of the references are listed.Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study
Nicholas J. DeVito et al.
LANCET (2020)
Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials
Dario Pasalic et al.
EUROPEAN JOURNAL OF CANCER (2020)
Improving the Time to Activation of New Clinical Trials at a National Cancer Institute-Designated Comprehensive Cancer Center
Erin Williams et al.
JCO ONCOLOGY PRACTICE (2020)
Racial and Ethnic Disparities Among Participants in US-Based Phase 3 Randomized Cancer Clinical Trials
Stephen R. Grant et al.
JNCI CANCER SPECTRUM (2020)
Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials
Emerson Y. Chen et al.
JAMA INTERNAL MEDICINE (2019)
Factors Associated With Age Disparities Among Cancer Clinical Trial Participants
Ethan B. Ludmir et al.
JAMA ONCOLOGY (2019)
Comparison of Sales Income and Research and Development Costs for FDA-Approved Cancer Drugs Sold by Originator Drug Companies
Kiu Tay-Teo et al.
JAMA NETWORK OPEN (2019)
Addressing Administrative and Regulatory Burden in Cancer Clinical Trials: Summary of a Stakeholder Survey and Workshop Hosted by the American Society of Clinical Oncology and the Association of American Cancer Institutes
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Interpreting Geographic Variations in Results of Randomized, Controlled Trials
Salim Yusuf et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Trends in National Institutes of Health Funding for Clinical Trials Registered in ClinicalTrials.gov
Stephan Ehrhardt et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Adult Cancer Clinical Trials That Fail to Complete: An Epidemic?
Kristian D. Stensland et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Industry Collaboration and Randomized Clinical Trial Design and Outcomes
Nitin Roper et al.
JAMA INTERNAL MEDICINE (2014)
Pancreatic Cancer Clinical Trials and Accrual in the United States
William A. Hoos et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Timely Completion of Scientifically Rigorous Cancer Clinical Trials: An Unfulfilled Priority
James H. Doroshow
JOURNAL OF CLINICAL ONCOLOGY (2013)
Implementation of Timeline Reforms Speeds Initiation of National Cancer Institute-Sponsored Trials
Jeffrey S. Abrams et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Steps and Time to Process Clinical Trials at the Cancer Therapy Evaluation Program
David M. Dilts et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Invisible barriers to clinical trials: The impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials
David M. Dilts et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Participation in cancer clinical trials - Race-, sex-, and age-based disparities
VH Murthy et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Pharmaceutical industry sponsorship and research outcome and quality: systematic review
J Lexchin et al.
BMJ-BRITISH MEDICAL JOURNAL (2003)
Share Paper
